Scientific and engineering studies of systems, structures, and components important to safety for a potential repository at Yucca Mountain, Nevada

TASK 26: Upgrade of Earthquake Simulation Facilities in the Large-Scale Structures Laboratory at University of Nevada Reno The objective of this Task was to purchase, install and commission the equipment necessary to upgrade two existing shake tables in the Structures Laboratory at UNR, from uniaxial to biaxial motion. It was recognized that a parallel effort, funded by NSF and HUD, to add a third biaxial table with identical properties to the upgraded existing tables, would be undertaken at the same time

Chiminey: Reliable Computing and Data Management Platform in the Cloud

The enabling of scientific experiments that are embarrassingly parallel, long running and data-intensive into a cloud-based execution environment is a desirable, though complex undertaking for many researchers. The management of such virtual environments is cumbersome and not necessarily within the core skill set for scientists and engineers. We present here Chiminey, a software platform that enables researchers to (i) run applications on both traditional high-performance computing and cloud-based computing infrastructures, (ii) handle failure during execution, (iii) curate and visualise execution outputs, (iv) share such data with collaborators or the public, and (v) search for publicly available data.Comment: Preprint, ICSE 201

Deciphering the Tsunami Wave Impact and Associated Connection Forces in Open-Girder Coastal Bridges

In view of the widespread damage to coastal bridges during recent tsunamis (2004 Indian Ocean and 2011 in Japan) large-scale hydrodynamic experiments of tsunami wave impact on a bridge with open girders were conducted in the Large Wave Flume at Oregon State University. The main objective was to decipher the tsunami overtopping process and associated demand on the bridge and its structural components. As described in this paper, a comprehensive analysis of the experimental data revealed that: (a) tsunami bores introduce significant slamming forces, both horizontal (Fh) and uplift (Fv), during impact on the offshore girder and overhang; these can govern the uplift demand in connections; (b) maxFh and maxFv do not always occur at the same time and contrary to recommended practice the simultaneous application of maxFh and maxFv at the center of gravity of the deck does not yield conservative estimates of the uplift demand in individual connections; (c) the offshore connections have to withstand the largest percentage of the total induced deck uplift among all connections; this can reach 91% and 124% of maxFv for bearings and columns respectively, a finding that could explain the damage sustained by these connections and one that has not been recognized to date; (e) the generation of a significant overturning moment (OTM) at the initial impact when the slamming forces are maximized, which is the main reason for the increased uplift in the offshore connections; and (f) neither maxFv nor maxOTM coincide always with the maximum demand in each connection, suggesting the need to consider multiple combinations of forces with corresponding moments or with corresponding locations of application in order to identify the governing scenario for each structural component. In addition the paper presents "tsunami demand diagrams", which are 2D envelopes of (Fh, Fv) and (OTM, Fv) and 3D envelopes of (Fh, Fv, OTM), as visual representations of the complex variation of the tsunami loading. Furthermore, the paper reveals the existence of a complex bridge inundation mechanism that consists of three uplift phases and one downward phase, with each phase maximizing the demand in different structural components. It then develops a new physics-based methodology consisting of three load cases, which can be used by practicing engineers for the tsunami design of bridge connections, steel bearings and columns. The findings in this paper suggest the need for a paradigm shift in the assessment of tsunami risk to coastal bridges to include not just the estimation of total tsunami load on a bridge but also the distribution of this load to individual structural components that are necessary for the survival of the bridge

Post-earthquake Reconnaissance Report on Transportation Infrastructure Impact of the February 27, 2010, Offshore Maule Earthquake in Chile

This report documents the findings and lessons learned from the February 27, 2010, M8.8 offshore Maule earthquake in Chile. Fewer than 0.15 percent of the bridges in Chile\u27s inventory, most built after 1995, collapsed or suffered damage that rendered them useless. Many spans of precast prestressed discontinuous girder bridges with continuous decks fell off their supports, probably due to significant in-plane rotation of the superstructure as a result of severe shaking. Lateral steel stoppers used to provide both vertical and lateral restraints on girders were largely unsuccessful due to their inadequate connection detail to cap beams and abutments. Reinforced concrete shear keys performed well as fuses limiting the transfer of excessive seismic loads from the superstructure to the foundation of bridges even though they could be optimized for maximum energy dissipation as part of the lateral restraint system at the bottom flange of girders. Vertical seismic bars were widely used to restrain the vertical motion of decks, and they also performed well. Bridge substructures (foundation, column, and cap beam) generally behaved satisfactorily except for two columns that suffered shear failure due to ground settlement and lateral spreading. All mechanically stabilized earth walls exceeded the expected performance

Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma

Patients with multiple myeloma commonly develop focal osteolytic bone disease, as well as generalised osteoporosis. The mechanisms underlying the development of osteoporosis in patients with myeloma are poorly understood. Although disruption of the RANKL/OPG pathway has been shown to underlie formation of focal osteolytic lesions, its role in the development of osteoporosis in myeloma remains unclear. Increased soluble RANKL in serum from patients with myeloma raises the possibility that this molecule plays a key role. The aim of the present study was to establish whether sRANKL produced by myeloma cells contributes directly to osteoporosis. C57BL/KaLwRij mice were injected with either 5T2MM or 5T33MM murine myeloma cells. 5T2MM-bearing mice developed osteolytic bone lesions (p<0.05) with increased osteoclast surface (p<0.01) and reduced trabecular bone volume (p<0.05). Bone volume was also reduced at sites where 5T2MM cells were not present (p<0.05). In 5T2MM-bearing mice soluble mRANKL was increased (p<0.05), whereas OPG was not altered. In contrast, 5T33MM-bearing mice had no changes in osteoclast surface or trabecular bone volume and did not develop osteolytic lesions. Soluble mRANKL was undetectable in serum from 5T33MM-bearing mice. In separate experiments, RPMI-8226 human myeloma cells were transduced with an human RANKL/eGFP construct, or eGFP alone. RPMI-8226/hRANKL/eGFP cells, but not RPMI-8226/eGFP cells, stimulated osteoclastic bone resorption (p<0.05) in vitro. Sub-cutaneous injection of NOD/SCID mice with RPMI-8226/hRANKL/eGFP or RPMI-8226/eGFP cells resulted in tumour development in all mice. RPMI-8226/hRANKL/eGFP-bearing mice exhibited increased serum soluble hRANKL (p<0.05) and a three-fold increase in osteoclast number (p<0.05) compared to RPMI-8226/eGFP-bearing mice. This was associated with reduced trabecular bone volume (27%, p<0.05), decreased trabecular number (29%, p<0.05) and increased trabecular thickness (8%, p<0.05). Our findings demonstrate that soluble RANKL produced by myeloma cells causes generalised bone loss, suggesting that targeting RANKL may prevent osteoporosis in patients with myeloma

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Performance of Transportation Infrastructure During Kumamoto Earthquakes of April 14 and 16, 2016\u2014 A Reconnaissance Report

DTFH61-07-00031This report described a reconnaissance effort to document bridge performance during the Kumamoto earthquakes in Japan in April 2016. More than 180 bridges were damaged by these earthquakes. Of particular interest is the performance of bridges that were relatively new (15\u201320 yr old) or recently retrofitted. Damage sustained was significant and included bearing and shear key failures, distortion and local buckling of the steel superstructures, and foundation movement. Most of the damage could be attributed to extensive slope failures and intense shaking close to the causative fault. Recommendations for improving bridge performance in future earthquakes are given

The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases

This article analyzes the "Global Burden of Disease Study 2010" and examines the study's implications for neglected tropical diseases

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention